How's the FemTech market doing these days?
In our femtech market deck, you will find everything you need to understand the market
SUMMARY
How's the FemTech market doing these days? FemTech is doing well, but the market has become much more selective about what deserves funding, scale, and buyer attention.
The strongest signal is that capital is coming back with a clearer filter. Investors are not funding “women’s wellness” broadly; they are backing companies that look like healthcare infrastructure.
The category is no longer defined by period trackers and fertility apps. The more important shift is that FemTech now spans menopause, maternal care, endometriosis diagnostics, pelvic health, metabolic health, benefits infrastructure, and AI-enabled clinical workflow.
Menopause has become the cleanest breakout wedge because it combines large unmet demand, recurring clinical needs, employer relevance, and real revenue momentum. Midi’s growth and valuation make the point much more strongly than category rhetoric ever could.
Employer and payer distribution is now one of FemTech’s biggest advantages. Maven, Progyny, Pomelo, and Carrot show that the market works best when women’s health can be sold as cost control, retention, access improvement, or risk reduction.
Pure DTC FemTech is under much more pressure than the headline funding rebound suggests. Flo can still win because it has rare scale, but most new apps now face weak differentiation, rising privacy scrutiny, and expensive consumer acquisition.
Clinic-heavy models are also being tested. Tia’s layoffs are a useful warning that strong women’s health demand does not automatically make hybrid clinic economics attractive.
Diagnostics may be one of the most interesting new infrastructure layers. Endometriosis is especially compelling because the problem is large, underdiagnosed, expensive, and still tied to slow or invasive diagnostic pathways.
AI is becoming useful in FemTech when it helps clinicians scale. The attractive use cases are triage, workflow, risk prediction, provider education, personalization, and monitoring rather than standalone chatbots pretending to deliver care.
Maternal health is investable again because the best companies are tying their products to measurable outcomes. Pomelo, Delfina, and Nadia Care show that the category becomes much stronger when it can point to preterm birth, NICU, hypertension, diabetes, access, and cost signals.
The unicorn bench is now real, with Maven, Flo, Pomelo, and Midi proving that billion-dollar FemTech outcomes exist across several models. The missing piece is still a deeper exit market, which means late-stage underwriting needs to stay disciplined.
The cleanest conclusion is that FemTech is in a strong selective maturation phase. The winners are moving away from lightweight wellness wrappers and toward infrastructure for high-cost, recurring, underserved women’s health needs.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Is money actually coming back into FemTech now?
Yes, FemTech funding is clearly back. However, the market is rewarding a narrower kind of company than before.
The latest funding pulse is too strong to dismiss as noise. PitchBook counted $1.2B of FemTech VC funding in 2024, while SVB’s broader women’s health definition reached $2.6B in 2024, up about 55% from 2023. Then 2026 started unusually fast: DLA Piper said Q1 2026 FemTech investment had already exceeded the whole of 2025, and April 2026 funding trackers counted roughly $674M raised in one month.
That sequence matters because it shows acceleration, not just isolated large rounds. The market had already recovered in 2024, held enough momentum through 2025, and then saw a visibly stronger start in 2026. If we compare that with broader digital health, where capital is still more disciplined after the 2021 bubble, FemTech is now one of the cleaner healthcare rebound stories.
But the funding is not loose. Recent deal lists show capital clustering around menopause platforms, maternal outcomes, diagnostics, fertility infrastructure, payer/employer benefits, and AI-enabled clinical workflow.
That tells us FemTech investors are now buying women’s health when it looks like healthcare infrastructure.
If you want more recent data on this point, please see our latest femtech market report.
Is FemTech still mostly period trackers and fertility apps these days?
No, FemTech is now much broader, and that broadening is one of the clearest signs that the market is maturing.
The company mix has changed. New funding trackers from 2024 to 2026 show activity across menopause, pelvic health, maternal care, endometriosis diagnostics, fertility benefits, bone health, breast and gynecologic cancer, metabolic health, and AI-enabled care coordination.
In other words, the category is becoming less dependent on cycle tracking and fertility as its default mental model.
The best-funded companies also tell that story. Maven, Pomelo, Midi, Carrot, Flo, and Progyny are no longer single-use-case companies in the way early FemTech was often framed. Maven sells women’s and family health across life stages. Pomelo is expanding from maternity into women’s and children’s care. Midi is moving from menopause into broader midlife and longevity care. Carrot is stretching from fertility into menopause and metabolic support.
That is important for investors because single-wedge FemTech used to feel small or niche.
Currently, the stronger companies are using a first wedge to build a longitudinal care platform.
The market is not “fertility plus period apps” anymore. Instead, it is becoming a set of entry points into expensive, recurring, underserved women’s health pathways.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Is menopause really the hottest FemTech wedge right now?
Yes, menopause is probably the cleanest breakout wedge in FemTech today.
Midi Health gives us the strongest proof. In 2025, it reported a $150M revenue run rate, up from $60M at the end of 2024, while serving about 20,000 patients per week. Then in February 2026, it raised a $100M Series D and crossed a $1B valuation. That is a very different signal from “menopause is under-discussed.”
It shows menopause can support real revenue velocity, clinical demand, insurance-backed delivery, and late-stage venture interest.
The wedge is also expanding beyond symptom treatment. Carrot pushed its AI-native metabolic program into menopause in May 2026, framing menopause around visceral fat, insulin resistance, cholesterol, blood pressure, sleep, stress, and energy. Flo’s 2024 growth round also pointed toward menopause and perimenopause expansion. Pomelo’s 2026 move beyond maternity adds another sign that midlife women’s care is becoming a platform layer, not a side module.
It’s easy to understand. Menopause works because it is large, recurring, medically complex, and still poorly served by traditional care. It also fits employer ROI better than many consumer wellness ideas, because symptoms affect retention, productivity, mental health, and chronic disease risk.
If you want more recent data on this point, please see our latest femtech market report.
Are employers and health plans buying FemTech now, or is it still consumer-led?
Employers and health plans are now one of the strongest demand channels in FemTech.
The employer signal has become more concrete lately. Maven’s 2026 benefits research found employers expanded women’s and family health benefits by 39% on average, while its 2025 report said two in three employers planned to invest in family health benefits within three years, a 44% jump from the prior year. That is not a small HR perk cycle. It suggests benefits teams are treating reproductive and family health as a retention, cost, and access issue.
Progyny shows the mature version of the model. Its fertility and pharmacy benefits businesses now represent a large public-company revenue base, with very high reported member satisfaction and long client retention. That matters because it proves the enterprise buyer exists at scale. FemTech does not have to rely only on consumers paying out of pocket for apps, coaching, or visits.
Pomelo is the newer proof point. In January 2026, it raised $92M at a $1.7B valuation after expanding through health plans and employers, covering more than 25M lives and nearly 7% of U.S. births. That is the kind of distribution investors care about: payer relationships, covered lives, measurable outcomes, and a reason for the buyer to renew.
So the FemTech market is currently strongest where the product can be sold as cost control, risk reduction, or workforce infrastructure.
This chart, included in our femtech market deck, shows annual VC investment in femtech startups
Are pure DTC FemTech apps still exciting these days?
Pure DTC FemTech apps are much harder to like today, unless they have scale, trust, or a clinical bridge.
Flo is the exception that proves the difficulty of the model. It had nearly 70M monthly active users and about 5M paid subscribers as of June 2024, then raised more than $200M at a valuation above $1B. Very few consumer FemTech companies have anything close to that distribution. For most new entrants, a cycle-tracking app, symptom journal, or content community is now too easy to copy and too expensive to scale.
Privacy pressure makes the DTC layer even harder. A 2025 Cambridge report described menstrual tracking data as a “gold mine” for advertisers because these apps can collect information on sex, medication, contraception, fertility intentions, hormones, diet, and exercise. A 2025 study of 45 female health apps found harmful permissions, sensitive data collection, and numerous third-party tracking libraries. On top of that, Premom’s FTC settlement and the Flo privacy litigation keep reminding users and regulators that reproductive data is not ordinary consumer data.
This does not kill consumer FemTech, but it changes the bar. The investable DTC company now needs either huge scale, unusually strong privacy architecture, a trusted clinical layer, or a path into reimbursed care.
Otherwise, the model risks becoming a pretty interface on top of sensitive data, which is exactly where regulators and users are becoming less forgiving.
Are FemTech clinic models still working now?
FemTech clinic models are under pressure right now unless they can prove operating leverage quickly.
Tia is the clearest warning signal. In October 2025, it cut about 23% of its workforce across corporate roles, providers, and field support after fundraising feedback pushed the company toward a faster profitability timeline. The detail matters: this was not just a marketing team cut or a temporary hiring freeze. It hit the labor structure that supports a hybrid in-person and virtual care model.
That gives us a useful read on the market. Investors still like women’s health care delivery, but they are far less patient with models that require clinics, local staffing, provider capacity, insurance contracting, and consumer acquisition all at once. In a higher-discipline funding environment, that mix starts to look heavy unless utilization and reimbursement are excellent.
The contrast with Midi and Pomelo is useful. Midi scales primarily through virtual menopause care, insurance coverage, provider training, and AI-enabled workflow. Pomelo scales through payer and employer distribution with outcome claims around maternity and pediatric care. Tia shows what happens when women’s health demand is real but the delivery model carries too much fixed cost.
These days, FemTech care delivery has to look more like scalable clinical infrastructure than a boutique clinic network.
If you want more recent data on this point, please see our latest femtech market report.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Is endometriosis diagnostics becoming a real FemTech opportunity?
Yes, endometriosis diagnostics is becoming one of the most interesting new FemTech opportunities.
The recent signal density is unusually high. In July 2025, Kephera launched EndomTest, described as the first commercially available non-invasive endometriosis diagnostic test in the U.S. In 2026, Serac’s imaging agent showed concordance with surgical findings in 16 of 19 cases and reported no false positives in a small study. Diamens raised funding in March 2026 to advance a menstrual-blood-based molecular diagnostic, while Endometrics won first prize in the NIH RADx Tech ACT ENDO Challenge for a non-invasive menstrual-blood approach.
Public funding is also pointing in the same direction. NIH’s ACT ENDO Challenge offered $3M in prizes to accelerate diagnostic technologies for endometriosis. ARPA-H’s Sprint for Women’s Health also put major non-dilutive funding behind women’s health innovation, including historically underfunded gynecologic conditions.
This is a stronger opportunity than another pain-tracking app because the bottleneck is structural. Endometriosis affects roughly one in ten women of reproductive age, diagnosis can take years, and definitive diagnosis has often relied on invasive pathways.
A credible non-invasive diagnostic would not just create a better user experience, but it could also change referral patterns, clinical trials, treatment timing, and reimbursement logic.
Is AI in FemTech useful now, or just a deck slide?
AI is useful in FemTech today when it helps clinicians scale. It is still shaky when it tries to replace clinical judgment, though.
The positive signals are concrete.
Midi says it is using AI to train providers on women’s health questions and support internal workflows, which makes sense in menopause because the evidence base is fragmented and many clinicians were never deeply trained in the area. Pomelo’s model uses data science to identify risk earlier in maternity care. Delfina raised $17M for AI-powered maternal health, with partners reporting improvements in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes. Carrot is also using AI-native metabolic support around menopause.
That is the investable version of AI in FemTech: workflow, triage, personalization, monitoring, provider education, and risk prediction. These use cases address real capacity constraints. They also make the business model stronger because AI can improve the margin profile of care delivery if it reduces repetitive clinical and administrative work.
The safety signal is equally important.
A 2025 women’s health benchmark across 13 large language models found roughly 60% failure rates, with “missed urgency” as a major weakness. A 2026 women’s health benchmark found no model averaging above 75% across expert-crafted clinical scenarios.
That means we should be excited about AI-enabled FemTech infrastructure, but not about free-floating women’s health chatbots pretending to be care.
If you want more recent data on this point, please see our latest femtech market report.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Is maternal health finally investable again?
Yes, maternal health is investable again because the strongest companies are selling actual outcomes.
Pomelo is the main proof. In January 2026, it raised $92M at a $1.7B valuation, covered more than 25M lives, and said its model had reduced preterm births, NICU admissions, and medical costs. It also supports nearly 7% of U.S. births. That is an unusually strong distribution signal for a women’s health company, especially because it comes through health plans, employers, and Medicaid relationships.
The second signal is that smaller maternal health companies are also finding capital when their model is tied to measurable improvement. Delfina raised $17M in 2025 for AI-powered proactive maternal care. Nadia Care, formerly Cayaba Care, raised $12M in March 2026 to expand community-centered maternal care, with a major national payer participating in the round. That payer participation is important because it suggests demand is not just coming from mission-aligned investors.
The reason maternal health works now is that the buyer pain is obvious. Preterm births, NICU admissions, unmanaged hypertension, gestational diabetes, postpartum depression, and access deserts are expensive and measurable.
When a FemTech company can credibly attach its product to those outcomes, the category stops sounding like wellness and starts sounding like risk management.
Are FemTech exits and unicorn outcomes becoming real now?
Yes, FemTech now has real breakout companies.
The unicorn bench is no longer empty. Maven reached a $1.7B valuation in 2024. Flo crossed a $1B valuation in 2024. Pomelo reached $1.7B in January 2026. Midi crossed $1B in February 2026. These are not tiny symbolic valuations; they are spread across benefits, consumer apps, maternity and pediatric care, and menopause/midlife care.
The quality of these companies also matters. Maven has broad employer distribution. Flo has rare consumer scale. Pomelo has payer and employer reach plus outcome claims. Midi has fast revenue growth and a focused clinical wedge. Together, they show that FemTech can produce different kinds of large companies rather than one narrow winner profile.
Still, exits have not caught up with valuations. The category has credible late-stage companies, but not yet a deep public-market or strategic-acquisition track record.
That makes the current market attractive but selective: investors can now believe in billion-dollar FemTech outcomes, while still needing to underwrite timing, buyer concentration, and exit route much more carefully than in larger healthcare software categories.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
So, how is the FemTech market doing these days?
FemTech is doing well now, and the evidence is strong enough to say that without hiding behind “mixed” consultant language.
The market is not booming everywhere, but the direction is positive. Funding has reaccelerated, the strongest categories are becoming clearer, and the best companies are moving from narrow products into broader care infrastructure. The attractive pockets today are menopause, maternal outcomes, endometriosis diagnostics, fertility and family benefits, payer/employer distribution, and AI-enabled clinical workflow.
The weak spots are also easy to see. Generic DTC apps face privacy, trust, and commoditization pressure. Hybrid clinic models are being forced to prove profitability faster. AI-only women’s health advice tools remain clinically risky unless they sit inside a guarded care model. That is not market weakness overall; it is the market becoming more disciplined.
So it looks like FemTech is currently in a strong, selective maturation phase. The opportunity is still very real, but it has moved away from lightweight wellness wrappers and toward infrastructure for high-cost, underdiagnosed, recurring women’s health needs.
| Check | Trend | Explanation |
|---|---|---|
| Funding pulse | Up | FemTech funding is clearly accelerating again, with strong 2024 totals and a sharp 2026 start. The rebound is concentrated in clinically serious companies, not spread evenly across every women’s wellness idea. |
| Category breadth | Up | The market has moved beyond fertility and period tracking into menopause, maternal care, diagnostics, pelvic health, bone health, metabolic health, and AI-enabled workflows. That breadth makes the category less fragile. |
| Menopause wedge | Up | Midi’s revenue growth, $1B+ valuation, and patient volume make menopause the clearest breakout wedge. Carrot, Flo, and Pomelo expanding into midlife care reinforce the same direction. |
| Employer/payer channel | Up | Maven, Progyny, Pomelo, and Carrot show that FemTech can sell through benefits, health plans, and employers. That channel is stronger than pure consumer acquisition because it ties FemTech to cost, retention, and outcomes. |
| Pure DTC apps | Down | Flo can still win because it has massive scale, but new DTC apps face privacy scrutiny and weak differentiation. The category now needs trust, clinical depth, or a bridge into reimbursed care. |
| Clinic models | Down | Tia’s 2025 layoffs show that hybrid clinic economics are being questioned. Women’s health demand is real, but clinic-heavy models need faster proof of utilization, reimbursement, and profitability. |
| Endometriosis diagnostics | Up | Kephera, Serac, Diamens, Endometrics, NIH, and ARPA-H all point to rising momentum around non-invasive diagnostics. This looks like one of the most interesting emerging FemTech infrastructure plays. |
| AI in FemTech | Mixed-up | AI is useful for provider training, triage, risk prediction, workflow, and personalization. Standalone women’s health chatbots remain unsafe because recent benchmarks show high failure rates. |
| Maternal health | Up | Pomelo, Delfina, and Nadia Care show renewed demand for maternal care models tied to measurable outcomes. This pocket works because the cost and clinical pain are both obvious. |
| Unicorn outcomes | Mixed-up | Maven, Flo, Pomelo, and Midi prove that billion-dollar FemTech companies now exist. The exit market remains thinner than the valuation story, so late-stage discipline still matters. |
| Overall market health | Up | FemTech is currently strong, but more selective. The winners are building care infrastructure for costly, underserved women’s health pathways rather than branding lightweight wellness products as healthcare. |
If you want more recent data on this point, please see our latest femtech market report.
OUR METHODOLOGY
The central question behind this analysis is not obvious from market intuition alone. FemTech still carries several competing narratives: that it is underfunded, that it is mostly period and fertility apps, that it is becoming serious healthcare infrastructure, or that recent momentum is just a few isolated funding rounds.
To make the answer clearer, we broke the market into the dimensions that matter most: funding momentum, category breadth, breakout wedges, buyer channels, consumer app pressure, clinic economics, diagnostics, AI use cases, maternal health, and late-stage outcomes.
For each dimension, we looked at recent signals rather than relying on category reputation or older assumptions. We prioritized signals that showed actual market behavior: funding totals, large rounds, revenue run rates, covered lives, employer and payer adoption, clinical outcome claims, regulatory pressure, diagnostic launches, AI benchmarks, layoffs, and valuation milestones.
No single signal carried the answer by itself. We used repeated evidence across categories to separate broad market recovery from narrower pockets of strength or pressure. That is why the conclusion is not simply that FemTech is “up” or “down.” The clearer read is that FemTech is currently strong, but much more selective.
The strongest areas are the ones where women’s health looks like infrastructure for expensive, recurring, underserved clinical needs. The weaker areas are the ones that still depend on lightweight consumer engagement, weak differentiation, or clinic-heavy models without clear operating leverage.
Key sources used for this analysis include: PitchBook on FemTech funding and VC market activity, SVB’s women’s health report, DLA Piper’s 2026 FemTech investment framing, Maven’s 2026 women’s and family health benefits research, Midi Health’s Series D and valuation announcement, Pomelo Care’s Series C announcement, Progyny reports and outcomes materials, Progyny annual reports, Flo Health’s growth round announcement, the FTC’s Premom settlement, Cambridge’s menstrual-tracking privacy report, Business Insider on Tia layoffs, Kephera’s EndomTest launch, Serac’s endometriosis imaging study, NIH’s RADx Tech ACT ENDO Challenge, ARPA-H’s Sprint for Women’s Health, Delfina’s AI-powered maternal health round, Nadia Care’s maternal care round, Carrot’s AI-native metabolic menopause expansion, and the Women’s Health Benchmark for LLMs.
This chart, featured in our femtech market deck, illustrates how revenue is divided among customer segments in the femtech market
Related blog posts
- How strong is fundraising in the femtech market right now?
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
